Mass spectrometry plays a key role in the translational proteomics pipeline: whereas continuous improvements in technologies at the discovery side increase qualitative and quantitative coverage of the entire proteoform diversity, ongoing optimization of methodologies at the clinical diagnostic site improve analytical quality and standardization. Integrating both ends would streamline the discovery of new biomarkers by increased analytical quality, and revolutionize clinical diagnostic assays by adoption of multi-protein strategies, including isoforms and post-translational modifications.
In this presentation Irene van den Broek PhD, Advanced Clinical Biosystems Research Institute at Cedars-Sinai Medical Center, will show both the potential of multiplexed multiple reaction monitoring MS to fulfill the quality requirements for clinical application as well as discuss challenges and potential strategies for clinical application of data-independent acquisition MS as a tool to quantify and identify myofilament proteoforms in heart biopsies.
For research use only. Not for use in diagnostic procedures.
